Logo

COYA

Coya Therapeutics, Inc.

COYA

Coya Therapeutics, Inc. • NASDAQ
$6.51 ▲ 2.04% (+0.13)
Market Cap $108.17 M
52w High $8.29
52w Low $4.65
Dividend Yield 0%
P/E -5.86
Volume 150.32K
Outstanding Shares 16.62M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $3.564M ▲ $5.474M ▼ $-2.116M ▲ -59.363% ▲ $-0.13 ▲ $-2.109M ▲
Q2-2025 $163.616K ▼ $6.571M ▲ $-6.095M ▲ -3.725K% ▼ $-0.36 ▲ $-6.088M ▲
Q1-2025 $257.884K ▲ $2.721M ▲ $-7.307M ▼ -2.833K% ▲ $-0.44 ▼ $-7.67M ▼
Q4-2024 $1.952K ▲ $2.145M ▼ $-2.916M ▲ -149.374K% ▼ $-0.18 ▲ $-4.073M ▲
Q3-2024 $0 $2.226M $-4.021M 0% $-0.26 $-4.443M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $28.13M ▼ $32.043M ▼ $4.758M ▼ $27.284M ▼
Q2-2025 $29.757M ▼ $33.453M ▼ $5.142M ▲ $28.31M ▼
Q1-2025 $35.531M ▼ $38.405M ▼ $5.035M ▲ $33.37M ▼
Q4-2024 $38.34M ▲ $44.347M ▲ $4.77M ▲ $39.577M ▲
Q3-2024 $31.057M $35.552M $3.542M $32.01M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-2.116M ▲ $-1.131M ▲ $-515.996K ▼ $19.137K ▲ $-1.627M ▲ $-1.131M ▲
Q2-2025 $-6.095M ▲ $-5.773M ▲ $0 $0 ▼ $-5.773M ▲ $-5.773M ▲
Q1-2025 $-7.307M ▼ $-2.828B ▼ $0 $19.137M ▲ $-2.809B ▼ $-2.828B ▼
Q4-2024 $-2.916M ▲ $-2.41M ▲ $0 $9.692M ▲ $7.282M ▲ $-2.41M ▲
Q3-2024 $-4.021M $-5.461M $0 $-56.332K $-5.518M $-5.461M

Five-Year Company Overview

Income Statement

Income Statement Coya is still a classic early‑stage biotech story: almost no product revenue yet and steady operating and net losses as it invests in development. Losses have been fairly small in absolute terms but persistent, reflecting spending on research, clinical activities, and listing costs rather than any commercial scale. Per‑share losses have bounced around, which is typical around an IPO and share issuances, but the pattern is consistent with a company still years away from meaningful sales and focused on building its pipeline rather than profitability.

Balance Sheet

Balance Sheet The balance sheet is small and simple. Assets are dominated by cash, with very limited physical assets or inventory, which is normal for a young biotech. Debt has effectively been cleared out, and shareholder equity has moved from negative to positive, signaling some recapitalization and a cleaner capital structure. That said, the absolute cash cushion appears modest, so the company’s financial flexibility and runway likely depend on carefully managing spending and securing additional funding over time.

Cash Flow

Cash Flow Cash flow reflects a company in build‑out mode: money flows out steadily to support operations, especially R&D and administrative costs, with no offsetting inflows from product sales. Free cash flow is negative but relatively contained in size, and there is essentially no heavy investment in equipment or facilities. This pattern suggests a lean, science‑driven organization that will typically need periodic external financing or partnerships to sustain its development plans until any future approvals or commercial deals.

Competitive Edge

Competitive Edge Coya operates in a highly competitive and crowded space—neurodegenerative and inflammatory diseases—where many large pharmaceutical and biotech players are active. Its edge comes from a sharp focus on Treg biology, a differentiated multi‑modal platform (biologics, cell therapy, and exosomes), and close ties to leading scientists in the field. The company’s patent portfolio around low‑dose IL‑2 formulations, combination therapies, and exosome engineering helps protect its niche. However, its small scale, early clinical stage, and the presence of much larger rivals mean its position is promising but still fragile and unproven.

Innovation and R&D

Innovation and R&D Innovation is the clear strength here. Coya is targeting regulatory T cells with several complementary approaches: a flagship dual‑mechanism biologic (COYA 302), a low‑dose IL‑2 formulation (COYA 301), a GLP‑1 combination program (COYA 303), personalized Treg cell therapy (COYA 101), and an engineered exosome platform licensed from a top research institution. Early clinical and preclinical signals in ALS, Alzheimer’s, and frontotemporal dementia are encouraging but still preliminary. The breadth of the platform offers multiple shots on goal, yet also requires sustained R&D spending and careful prioritization of which indications and modalities to advance first.

Summary

Overall, Coya looks like a very early‑stage, science‑heavy biotech: minimal revenue, recurring but manageable losses, a cash‑centric balance sheet with no current debt, and negative cash flow driven by R&D. Its real value proposition lies in its Treg‑focused platform, exosome technology, and growing intellectual property, all aimed at tough neurodegenerative and inflammatory diseases. The opportunity is significant if clinical trials continue to validate the approach, but the company still faces the usual biotech risks: scientific uncertainty, regulatory hurdles, dependence on external capital, and intense competition from larger players pursuing the same disease areas with different technologies.

NEWS

November 25, 2025 · 8:00 AM UTC

Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences

Read more

November 12, 2025 · 8:00 AM UTC

Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update

Read more

November 4, 2025 · 8:00 AM UTC

Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo

Read more

October 27, 2025 · 4:01 PM UTC

Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter's Option to Purchase Additional Shares

Read more

October 24, 2025 · 6:30 AM UTC

Coya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common Stock

Read more